{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:07:07Z","timestamp":1780103227142,"version":"3.54.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Case Reports"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jaccas.2025.106407","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T12:37:34Z","timestamp":1765370254000},"page":"106407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic Plasma Exchange and Evinacumab for Homozygous Familial Hypercholesterolemia"],"prefix":"10.1016","volume":"31","author":[{"given":"Sawye","family":"Raygani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra Vaio","family":"Sykes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber P.","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph L.","family":"Witztum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaccas.2025.106407_bib1","series-title":"EVKEEZA (Evinacumab-Dgnb) Injection: Prescribing Information","year":"2025"},{"issue":"7","key":"10.1016\/j.jaccas.2025.106407_bib2","doi-asserted-by":"crossref","first-page":"665","DOI":"10.5551\/jat.RV17050","article-title":"Homozygous familial hypercholesterolemia","volume":"28","author":"Nohara","year":"2021","journal-title":"JAT"},{"issue":"3","key":"10.1016\/j.jaccas.2025.106407_bib3","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1006\/geno.1999.6041","article-title":"Identification of a mammalian angiopoietin-related protein expressed specifically in liver","volume":"62","author":"Conklin","year":"1999","journal-title":"Genomics"},{"issue":"37","key":"10.1016\/j.jaccas.2025.106407_bib4","doi-asserted-by":"crossref","first-page":"33742","DOI":"10.1074\/jbc.M203215200","article-title":"ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase","volume":"277","author":"Shimizugawa","year":"2002","journal-title":"J Biol Chem"},{"issue":"23","key":"10.1016\/j.jaccas.2025.106407_bib5","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1002926","article-title":"Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia","volume":"363","author":"Musunuru","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jaccas.2025.106407_bib6","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1194\/jlr.M054890","article-title":"ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys","volume":"56","author":"Gusarova","year":"2015","journal-title":"J Lipid Res"},{"issue":"8","key":"10.1016\/j.jaccas.2025.106407_bib7","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jaccas.2025.106407_bib8","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1161\/ATVBAHA.124.322364","article-title":"Real-world effectiveness and safety of evinacumab in children and adults with homozygous familial hypercholesterolemia: a multisite US perspective\u2014brief report","volume":"45","author":"Wilkinson","year":"2025","journal-title":"ATVB"},{"issue":"11","key":"10.1016\/j.jaccas.2025.106407_bib9","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3390\/ph15111389","article-title":"Long-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia: real-world clinical experience","volume":"15","author":"Stefanutti","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"2","key":"10.1016\/j.jaccas.2025.106407_bib10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/jca.22043","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice \u2013 evidence-based approach from the writing committee of the American Society for Apheresis: the ninth special issue","volume":"38","author":"Connelly-Smith","year":"2023","journal-title":"J Clin Apher"},{"issue":"7918","key":"10.1016\/j.jaccas.2025.106407_bib11","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(75)92193-5","article-title":"Plasma exchange in the management of homozygous familial hypercholesterolaemia","volume":"305","author":"Thompson","year":"1975","journal-title":"Lancet"},{"issue":"6510","key":"10.1016\/j.jaccas.2025.106407_bib12","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1136\/bmj.291.6510.1671","article-title":"Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange","volume":"291","author":"Thompson","year":"1985","journal-title":"BMJ"}],"container-title":["JACC: Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666084925031948?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666084925031948?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:41:55Z","timestamp":1780101715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666084925031948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2666084925031948"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccas.2025.106407","relation":{},"ISSN":["2666-0849"],"issn-type":[{"value":"2666-0849","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic Plasma Exchange and Evinacumab for Homozygous Familial Hypercholesterolemia","name":"articletitle","label":"Article Title"},{"value":"JACC: Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccas.2025.106407","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"106407"}}